Tumor‐Targeting Co‐Delivery of T‐Cell Antigen and Camptothecin Guided by Cascade‐Responsive Peptide Self‐Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.202516767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Yinghao Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou…. Hauptthemen laut MEDLINE: Camptothecin, Immunotherapy, Antigens, Neoplasm, Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Discipline Cluster of Oncology of Wenzhou Medical University of China, Wenzhou High-Level Innovation Team.
Abstract (Originalsprache)
Antigen presentation deficiency restricted by class I major histocompatibility complex (MHC‐I) causes low antigenicity and antigen escape in tumors, thereby limiting T‐cell immunotherapy outcomes. Here, a combined tumor immunotherapy is developed, in which tumors can present exogenous non‐tumor antigens, and adoptively transferred CD8 + T cells specific for these antigens are re‐targeted to attack tumors. The approach leverages a cascade‐responsive peptide self‐assembly to co‐deliver suitable antigens and the chemotherapeutic drug camptothecin (CPT) to tumors. As a proof‐of‐concept, to re‐target ovalbumin (OVA)‐specific OT‐I CD8 + T cells against tumors, PSA (Nap‐GFFpYE‐ss‐Ag) and CPSA (CPT‐GFFpYE‐ss‐Ag) are constructed, containing an OVA‐derived epitope OVA 257‐264 and/or CPT. The design enables the release of a unique N‐terminal extended OVA 257‐264 and CPT into the cytosol. As a result, the extended antigen is efficiently presented on the tumor surface by MHC‐I, and CPT further enhances this presentation. When combined with adoptively transferred OT‐I CD8 + T cells, the approach effectively facilitates CD8 + T cell infiltration and tumor inhibition. Additionally, CPSA treatment sensitizes immune responses to programmed cell death‐ligand 1 (PD‐L1) blockade, allowing the approach to synergize with an anti‐PD‐L1 antibody for improved tumor eradication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, P. R. China.
- Key Laboratory of Bioactive Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
ORCID-Profile: Zhi-Wen Hu
Förderung
- National Natural Science Foundation of China
- the Discipline Cluster of Oncology of Wenzhou Medical University of China
- Wenzhou High-Level Innovation Team
Zitieren
APA
Ding, Y., Zhu, X., Wen, J., Xiong, J., Zhang, S., Yang, Z., & Hu, Z. W. (2026). Tumor‐Targeting Co‐Delivery of T‐Cell Antigen and Camptothecin Guided by Cascade‐Responsive Peptide Self‐Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202516767
Vancouver
Ding Y, Zhu X, Wen J, Xiong J, Zhang S, Yang Z, et al. Tumor‐Targeting Co‐Delivery of T‐Cell Antigen and Camptothecin Guided by Cascade‐Responsive Peptide Self‐Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202516767
BibTeX
@article{Ding2026,
author = {Ding, Yinghao and Zhu, Xueying and Wen, Jian and Xiong, Junchao and Zhang, Shengyi and Yang, Zhimou and Hu, Zhi-Wen},
title = {Tumor‐Targeting Co‐Delivery of T‐Cell Antigen and Camptothecin Guided by Cascade‐Responsive Peptide Self‐Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202516767}
}
EUVIMED